Alveolar epithelial lining fluid cellularity, protein and endothelin-1 in children with congenital heart disease


ABSTRACT: This study applied bronchoalveolar lavage (BAL) to children with congenital heart disease (CHD) prior to elective cardiac catheterization (n=48), to determine the influence of pulmonary blood flow and viral infection on the alveolar epithelial lining fluid (ELF) concentration of leucocytes, protein and endothelin-1 (ET-1).

Lower respiratory tract (LRT) viral infection was defined as either a positive immunofluorescence for virus, or a virus cultured from the bronchoalveolar lavage fluid (BALF). Haemodynamic status was determined at cardiac catheterization. Normative data for BALF, but not ELF parameters, were obtained from 26 asymptomatic, noninfected normal children undergoing elective surgery.

In the absence of LRT infection, the BALF macrophage, lymphocyte and neutrophil differential in CHD was not significantly different from the normal controls. In CHD, both increased pulmonary-to-systemic flow ratio (Qp/Qs) and increased pulmonary artery-to-left ventricular pressure ratio PAP/LVP were associated with a decrease in ELF protein (r = -0.59; p<0.0001; and r = -0.50; p<0.0001 respectively). A respiratory virus was isolated from the BALF in 8 (17%) of CHD children. Virus isolation was associated with an increased ELF total protein (p<0.05 vs no infection), a decreased alveolar macrophage differential count (p<0.01), and an increased neutrophil differential count (p<0.05). ET-1 was detected in the BALF of 83% of the noninfected CHD children compared to only 23% of the controls (p<0.001). ELF ET-1 concentrations did not correlate with haemodynamic status in CHD, but were up to 100 times higher than paired plasma levels.

We conclude that, in congenital heart disease, both lower respiratory tract viral infection and increased pulmonary blood flow and/or pulmonary vascular pressure influence the alveolar milieu. High alveolar epithelial lining fluid concentrations of endothelin-1 occur in congenital heart disease, but the stimulus for pulmonary endothelin-1 production is unclear.


The effect of congenital intracardiac shunts on the profile of alveolar cells and solutes is unknown. However, there is indirect evidence that changes in the alveolar milieu are present in paediatric congenital heart disease (CHD). For example, decreased pulmonary compliance, tachypnoea, wheezing and cough are associated with an increased pulmonary artery-to-left ventricular pressure ratio PAP/LVP were associated with a decrease in ELF protein (r = -0.59; p<0.0001; and r = -0.50; p<0.0001 respectively). A respiratory virus was isolated from the BALF in 8 (17%) of CHD children. Virus isolation was associated with an increased ELF total protein (p<0.05 vs no infection), a decreased alveolar macrophage differential count (p<0.01), and an increased neutrophil differential count (p<0.05). ET-1 was detected in the BALF of 83% of the noninfected CHD children compared to only 23% of the controls (p<0.001). ELF ET-1 concentrations did not correlate with haemodynamic status in CHD, but were up to 100 times higher than paired plasma levels.

We conclude that, in congenital heart disease, both lower respiratory tract viral infection and increased pulmonary blood flow and/or pulmonary vascular pressure influence the alveolar milieu. High alveolar epithelial lining fluid concentrations of endothelin-1 occur in congenital heart disease, but the stimulus for pulmonary endothelin-1 production is unclear.


The effect of congenital intracardiac shunts on the profile of alveolar cells and solutes is unknown. However, there is indirect evidence that changes in the alveolar milieu are present in paediatric congenital heart disease (CHD). For example, decreased pulmonary compliance, tachypnoea, wheezing and cough are associated with an increased pulmonary artery-to-left ventricular pressure ratio PAP/LVP were associated with a decrease in ELF protein (r = -0.59; p<0.0001; and r = -0.50; p<0.0001 respectively). A respiratory virus was isolated from the BALF in 8 (17%) of CHD children. Virus isolation was associated with an increased ELF total protein (p<0.05 vs no infection), a decreased alveolar macrophage differential count (p<0.01), and an increased neutrophil differential count (p<0.05). ET-1 was detected in the BALF of 83% of the noninfected CHD children compared to only 23% of the controls (p<0.001). ELF ET-1 concentrations did not correlate with haemodynamic status in CHD, but were up to 100 times higher than paired plasma levels.

We conclude that, in congenital heart disease, both lower respiratory tract viral infection and increased pulmonary blood flow and/or pulmonary vascular pressure influence the alveolar milieu. High alveolar epithelial lining fluid concentrations of endothelin-1 occur in congenital heart disease, but the stimulus for pulmonary endothelin-1 production is unclear.


The effect of congenital intracardiac shunts on the profile of alveolar cells and solutes is unknown. However, there is indirect evidence that changes in the alveolar milieu are present in paediatric congenital heart disease (CHD). For example, decreased pulmonary compliance, tachypnoea, wheezing and cough are associated with an increased pulmonary artery-to-left ventricular pressure ratio PAP/LVP were associated with a decrease in ELF protein (r = -0.59; p<0.0001; and r = -0.50; p<0.0001 respectively). A respiratory virus was isolated from the BALF in 8 (17%) of CHD children. Virus isolation was associated with an increased ELF total protein (p<0.05 vs no infection), a decreased alveolar macrophage differential count (p<0.01), and an increased neutrophil differential count (p<0.05). ET-1 was detected in the BALF of 83% of the noninfected CHD children compared to only 23% of the controls (p<0.001). ELF ET-1 concentrations did not correlate with haemodynamic status in CHD, but were up to 100 times higher than paired plasma levels.

We conclude that, in congenital heart disease, both lower respiratory tract viral infection and increased pulmonary blood flow and/or pulmonary vascular pressure influence the alveolar milieu. High alveolar epithelial lining fluid concentrations of endothelin-1 occur in congenital heart disease, but the stimulus for pulmonary endothelin-1 production is unclear.

of normal children undergoing routine surgery. Since plasma for urea was not obtained from the normal controls, only BAL fluid (BALF) leucocyte concentrations were determined.

Methods

Subjects

All children with CHD undergoing elective cardiac catheterization were eligible for BAL. Forty-eight children with CHD were studied from August 1993 until July 1994. The study was approved by the Ethics in Human Research Committee of the Royal Children’s Hospital and required full informed, written parental consent. The day before cardiac catheterization and without prior knowledge of the pulmonary haemodynamic status, a respiratory symptom history was obtained and the child was examined for abnormal respiratory signs. Children with rhinitis were diagnosed as having upper respiratory tract symptoms. LRT symptoms/signs were classified as the presence of cough, tachypnoea, retractions, wheeze or crackles. If the awake respiratory rate was >50 breaths·min⁻¹, the sleeping respiratory rate was measured. Tachypnoea was defined as a sleeping respiratory rate >50 breaths·min⁻¹, i.e. greater than the 95th percentile for this age range [11]. Normal controls were obtained from children undergoing elective posterior medial release for club feet (n=24) and ureteric reimplantation (n=2). Children with chronic respiratory conditions, LRT symptoms or LRT infection were excluded as controls. Haemodynamic measurements were not performed on the normal controls.

Bronchoalveolar lavage

Immediately prior to cardiac catheterization, or elective surgery, BAL was performed by a single operator (JG) using a modification of the technique described by KOMBOURLIS and KURLAND [12]. Apart from the mode of delivery, NB-BAL was identical to our standardized fibreoptic BAL protocol [13]. Children were anaesthetized with isoflurane, intravenous thiopentone and pancuronium. Immediately after intubation and with the child’s head turned to the left, a 6, 7 or 8 French straight 60 cm end hole suction catheter (Vygon S.A., Écouen, France) was inserted into the endotracheal (ET) tube through a right-angle swivel bronchoscope connector (Mallinckrodt Medical Pty. Ltd, Australia). The suction catheter size was determined by the diameter of the ET tube. The catheter was advanced until wedged, 1 mL·kg⁻¹ body weight (BW) saline instilled and BALF immediately aspirated into a suction trap via a three-way tap using 150 mmHg negative pressure. Without removing the catheter, two further aliquots of 1 mL·kg⁻¹ BW saline were then instilled and aspirated. Pooled BALF was placed on ice for processing. A sample of BALF underwent bacteriological and virological analysis. In total, the lavage procedure lasted less than 30 s. The BALF total cell concentration was determined by haemocytometer and a cell preparation obtained by Cytospin at 900 rpm for 5 min (Cytospin 2; Shandon Products Ltd, UK). BALF cells were stained with Wilson’s stain reagents. Under oil microscopy (×1,000 magnification), specific leucocyte differential counts (%) were calculated from >300 leucocytes. BALF leucocyte concentrations were calculated after correcting for epithelial cells. Cell-free supernatant was obtained by centrifugation of BALF at 1,000g for 10 min (4°C) and 8,000g for a further 3 min (4°C). Cell-free BALF was stored at -70°C. Blood was not obtained from normal control children for ethical reasons.

Cardiac catheterization

Catheterization was performed under general anaesthesia and the fractional concentration of inspired oxygen maintained at 0.3. Pressure measurements were obtained using fluid-filled catheters connected to pressure transducers. The Qp/Qs was calculated from the Fick principle [14]. Two haemodynamic variables were recorded for this study, Qp/Qs and the ratio of systolic pulmonary artery-to-systolic left ventricular pressure (PAP/LVP). Other haemodynamic measurements were recorded as indicated for the cardiac investigation, but were not analysed in this study. During catheterization, blood was sampled from the left ventricle and was analysed for total protein and urea using routine hospital biochemical techniques. Left ventricular blood was also collected into a chilled ethylenediamine tetra-acetic acid (EDTA) coated tube, transported immediately on ice and centrifuged at 1,000g for 15 min at 4°C. Plasma was stored at -70°C for ET-1 analysis.

BALF microbiology and virology

Samples of BALF were analysed for viruses using immunofluorescence and cytopathic effect during culture with human fibroblasts, monkey kidney and Helen-Lake (HeLa) cell lines. All common respiratory viruses, including coronavirus, could be identified with this combination. If nasal secretions were present, a nasopharyngeal aspirate (NPA) was performed. Primary, secondary and tertiary aerobic and anaerobic bacteriological cultures were performed using 10 µL of BALF. All potential bacterial pathogens were identified and reported using a semi-quantitative analysis that had previously been validated using quantitative BALF cultures from children with cystic fibrosis (<10⁴ colony forming units (cfu)·mL⁻¹, 10⁴–10⁶ cfu·mL⁻¹, and >10⁶ cfu·mL⁻¹) (D. Armstrong, personal communication). Bacterial cultures could not detect Chlamydiae or Mycoplasma pneumoniae. LRT infection was defined as either the detection of a virus from the BALF and/or the isolation of a bacterial pathogen at concentrations of ≥10⁴ cfu·mL⁻¹ [15].

BALF total protein, albumin and urea

All assays were performed using a Roche Cobas Bio centrifugal analyser (Roche Diagnostics, Basel, Switzerland). Total protein in 50 µL BALF was determined using benzethonium chloride [16]. The linear dynamic range for
the assay was from 0.03–0.4 g·L⁻¹. BALF urea was measured after extraction of the peptide. The ET-1 RIA used a commercial antiserum (Peninsula Laboratories, Belmont, CA, USA) at the recommended dilution in a volume of 100 µL. Cross-reactivity to human ET-1 was 100%, 7% for endothelin-2 and -3 (ET-2 and ET-3) and 17% for big ET-1. Tracer (²⁵¹ET-1) was purchased from Amersham International plc. (U.K.) and used at a concentration of approximately 10,000 counts per minute (cpm)-100 µL⁻¹. Synthetic ET-1 (Peninsula Laboratories) was used as the standard in a range of 0.5–500 pg·100 µL⁻¹ tube. The assay buffer was sodium phosphate (0.1 M), pH 7.4, with 0.1% Triton-X 100 and 0.1% bovine serum albumin. After a 24 h incubation at 4°C, separation of antibody-bound ET-1 from free ET-1 was achieved with 100 µL of Sac-Cel solid phase second antibody coated cellulose suspension (anti-rabbit; I.D.S., Washington). Supernatants were aspirated and the bound fractions in the pellet counted. The limit of detection of the assay was 0.5 pg·tube⁻¹.

**Endothelin-1 assay**

ET-1 was measured in BALF and plasma by radioimmunoassay (RIA). All plasma samples were measured after extraction of the peptide. The ET-1 RIA used a commercial antiserum (Peninsula Laboratories, Belmont, Ca, USA) at the recommended dilution in a volume of 100 µL. Cross-reactivity to human ET-1 was 100%, 7% for endothelin-2 and -3 (ET-2 and ET-3) and 17% for big ET-1. Tracer (²⁵¹ET-1) was purchased from Amersham International plc. (U.K.) and used at a concentration of approximately 10,000 counts per minute (cpm)-100 µL⁻¹. Synthetic ET-1 (Peninsula Laboratories) was used as the standard in a range of 0.5–500 pg·100 µL⁻¹ tube. The assay buffer was sodium phosphate (0.1 M), pH 7.4, with 0.1% Triton-X 100 and 0.1% bovine serum albumin. After a 24 h incubation at 4°C, separation of antibody-bound ET-1 from free ET-1 was achieved with 100 µL of Sac-Cel solid phase second antibody coated cellulose suspension (anti-rabbit; I.D.S., Washington). Supernatants were aspirated and the bound fractions in the pellet counted. The limit of detection of the assay was 0.5 pg·tube⁻¹.

**Plasma ET-1.** Plasma samples were centrifuged at 4°C after thawing. Trifluoroacetic acid (TFA; 0.5 mL, 0.1%) was added to each 0.5 mL aliquot of plasma. After blending in a vortex mixer, plasma samples were centrifuged (4°C) and loaded onto Sep-Pak C₁₈ cartridges (Waters, Millipore, MA, USA) containing 0.5 mL assay buffer. Final elution was with 3 mL 80% methanol and 0.1% TFA. Extracts were dried overnight, reconstituted in 500 µL of assay buffer, and 200 µL aliquots were assayed in triplicate. Recovery of added ET-1 to plasma was 73% (range 66–79%) for 25–100 pg added ET-1. The limit of detection for samples was 1.6 pg·mL⁻¹ of plasma extract. Plasma ET-1 from normal controls was not measured.

**BALF ET-1.** Because of limited BALF sample volume, ET-1 was measured directly on 200 µL of BALF. For each BALF-RIA, a standard curve was constructed from assay tubes containing the usual quantities of antibody tracer and standard (as described above), but with the addition of 200 µL BALF from a normal subject with a negligible level of ET-1. The final volumes of standard and sample tubes were equalized to 500 µL. The limit of detection of direct measurements of standard ET-1 added to BALF was 2.5 pg·mL⁻¹. Interassay CoV on BALF samples was 15% at 3.9 pg and 7.4% at 15 pg. The addition of BALF to the assay standard curve avoided problems associated with interference from nonspecific substances in unextracted BALF. There was sufficient

**Calculation of ELF volume**

ELF volume was calculated using the urea dilution technique [17]. The ELF concentration was not calculated when the BALF concentration of solute was below the assay detection limit. Blood urea was not available for the normal controls and ELF concentrations of cells and solutes were not estimated.

**Statistical analysis**

Data was analysed using Statistical Package for the Social Sciences (SPSS®) for Windows® (SPSS Inc., Chicago, IL, USA). Results are expressed as median and interquartile range, unless indicated [18]. Univariate comparisons between groups were performed by using the Mann-Whitney U-test. Correlations were obtained using Spearman’s rank correlation (coefficient=r_s). Proportions were compared using the Chi-squared test. Stepwise multivariate linear regression analysis was performed after normalization of residuals by log_10 transformation. Statistical significance was accepted for p-values less than 0.05.

**Results**

The clinical diagnoses of children with CHD are described in table 1. Q_p/Q_s ratios were calculated for all CHD children (n=48) and PAP/LVP ratios calculated in all but one child. Twenty two CHD children (46%) had increased pulmonary blood flow as defined by a Q_p/Q_s ≥1.5, and eight (17%) had increased pulmonary vascular pressure (PAP/LVP ≥0.5). Elevations in vascular pressure were all related to increased pulmonary blood flow, and the correlation between Q_p/Q_s and PAP/LVP was,
therefore, significant ($r_s = 0.65; p<0.0001$). BAL was well-tolerated, with no clinically significant decrease in oxygen saturation during or after the procedure.

**LRT infection and CHD**

Forty CHD children had no LRT infection (noninfected group). A virus was isolated from the BALF of eight children (infected group). In five children, LRT viral infection was associated with *Moraxella catarrhalis* and/or *Haemophilus influenzae* at levels $\geq 10^4$ cfu·mL$^{-1}$ (table 2). No child had a LRT bacterial infection alone. LRT viral infection was associated with a lower percentage of alveolar macrophages, a higher percentage of neutrophils and increased concentrations of neutrophils, lymphocytes and eosinophils (fig. 1 and table 3).

LRT infection was associated with increased ELF concentrations of total protein (fig. 2 and table 3). Plasma protein was measured in five children with LRT infection and the ELF plasma total protein ratio was increased in this subgroup (table 3). Multivariate analysis confirmed an independent association between LRT viral infection and both increased ELF total protein and increased ELF total cell concentrations (table 4).

**Table 2.** – Clinical details of congenital heart disease children with an intercurrent lower respiratory tract infection

<table>
<thead>
<tr>
<th>Pt No</th>
<th>Diagnosis</th>
<th>$Q'_p/Q'_s$</th>
<th>Respiratory symptoms</th>
<th>NPA virus</th>
<th>BALF virus</th>
<th>BALF bacteria</th>
<th>Bacteria in neutrophils</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PVS</td>
<td>1.0</td>
<td>Nil</td>
<td>CMV</td>
<td>CMV</td>
<td>No growth</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>TA, PAPVD</td>
<td>2.9</td>
<td>Retr., Tachy</td>
<td>CMV</td>
<td>CMV</td>
<td>M. cat. ($&gt;10^6$)</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>CoA</td>
<td>1.0</td>
<td>Nil</td>
<td>Not done*</td>
<td>Rhinovirus</td>
<td>H. infl. ($&gt;10^6$)</td>
<td>No</td>
</tr>
<tr>
<td>4</td>
<td>VSD</td>
<td>3.0</td>
<td>Retr., Tachy, Cough</td>
<td>CMV</td>
<td>Parainfluenza</td>
<td>M. cat. ($&gt;10^6$)</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>VSD</td>
<td>1.4</td>
<td>Rhinitis</td>
<td>Rhinovirus</td>
<td>CMV</td>
<td>No growth</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>VSD</td>
<td>3.0</td>
<td>Rhinitis, Retr., Tachy, Cough</td>
<td>Not done*</td>
<td>Rhinovirus</td>
<td>M. cat. ($10^6$)</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>ASD</td>
<td>1.8</td>
<td>Cough</td>
<td>Not done*</td>
<td>Rhinovirus</td>
<td>M. cat. ($10^6$)</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>Fallot's</td>
<td>1.0</td>
<td>Cough</td>
<td>Not done*</td>
<td>RSV</td>
<td>No growth</td>
<td>No</td>
</tr>
</tbody>
</table>

Pt: patient; $Q'_p/Q'_s$: ratio of pulmonary-to-systemic blood flow; NPA: nasopharyngeal aspirate; BALF: bronchoalveolar lavage fluid; TA: tricuspid atresia; PAPVD: partial anomalous pulmonary venous drainage; Retr.: retractions; Tachy.: tachypnoea; CMV: cytomegalovirus; RSV: respiratory syncytial virus; M. cat.: *Moraxella catarrhalis*; H. infl.: *Haemophilus influenzae*; $>10^6$ and $\geq 10^6$: colony forming units·mL$^{-1}$. *: no secretions in nasopharynx. For further definitions see legend to table 1.
Pulmonary haemodynamics and CHD

In the noninfected group, there was no correlation between pulmonary haemodynamic changes (Qp/Qs, PAP/LVP) and the percentage of macrophages and neutrophils (fig. 1). However, there was a trend for the ELF total cell concentration to decrease with increased Qp/Qs (rs= -0.57; p=0.06). The ELF total protein concentration decreased with increased PAP/LVP (r= -0.50; p<0.0001) and increased Qp/Qs (r= -0.59; p<0.0001) (fig. 2). The ELF/plasma total protein ratio also decreased with increased Qp/Qs (r= -0.46; p<0.05) and PAP/LVP (r= -0.41; p<0.05), in the subgroup where plasma total protein was measured (n=24). PAP/LVP and Qp/Qs were collinearly associated and both variables were independently associated with decreased ELF total protein when entered separately into the regression model (table 4).

Endothelin-1 and CHD

Thirty two plasma samples from CHD children were available for ET-1 analysis. There was a trend for plasma ET-1 concentration to decrease with age (rs= 0.32; p=0.09), but there was no significant correlation between plasma ET-1 and haemodynamic status. There was a trend for plasma ET-1 to be higher with LRT infection (p=0.09) (table 3).

In CHD, the concentration of ET-1 in ELF could be estimated in 37 BALF samples. ELF ET-1 was always above the paired plasma concentration (median ELF vs plasma: 280 vs 7.1 pg·mL⁻¹), with no correlation between the plasma and ELF concentrations (fig. 3). There was no significant correlation between ELF ET-1 and either Qp/Qs (fig. 4) or PAP/LVP. The ELF ET-1 concentration was significantly lower in LRT viral infection (fig. 4 and table 3).

Table 4. – Final stepwise multivariate models with epithelial lining fluid measurements as the dependent variables in children with CHD

<table>
<thead>
<tr>
<th>Dependent variable</th>
<th>n</th>
<th>R²</th>
<th>LRT infection</th>
<th>Qp/Qs (log¹⁰b)</th>
<th>Other variables†</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELF total protein (log₁₀)</td>
<td>48</td>
<td>0.31</td>
<td>0.341 (0.08)***</td>
<td>-0.433 (0.15)**</td>
<td>NS</td>
</tr>
<tr>
<td>ELF total cell concentration</td>
<td>48</td>
<td>0.24</td>
<td>0.500 (0.13)***</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

β: standardized regression coefficient; se β: standard error of β; *: ratio of systolic pulmonary artery pressure to systolic left ventricular also significant if entered instead of Qp/Qs; †: variables entered but never reached significance were: age, sex, weight, % bronchoalveolar fluid return, previous operation, and previous wheeze. **: p<0.01; ***: p<0.001. For further definitions see legend to table 3.
Respiratory symptoms and CHD

LRT symptoms were present in CHD children with and without LRT viral infection (table 3). Noninfected children with LRT symptoms had higher $Q_{p}/Q_{s}$ and PAP/LVP ratios compared to noninfected children without LRT symptoms (table 5). Respiratory symptoms associated with high $Q_{p}/Q_{s}$ or PAP/LVP were not associated with changes in the alveolar leucocyte differential (table 5), but they were associated with a lower ELF total protein concentration.

Comparison of CHD with normal controls

There was no significant difference in BALF alveolar macrophage and lymphocyte differentials between noninfected CHD children and normal controls (table 6). BALF ET-1 was above the detection limit (2.5 pg·mL$^{-1}$) in 83% of the 36 CHD children with no LRT infection compared to 23% of the normal controls ($p<0.001$) (fig. 5 and table 6).

Table 5. – Comparison of noninfected CHD children with and without lower respiratory tract symptoms

<table>
<thead>
<tr>
<th>Congenital heart disease group</th>
<th>No LRT symptoms (n=32)</th>
<th>LRT symptoms (n=8)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$Q_{p}/Q_{s}$</td>
<td>1.0 (0.8–1.7)</td>
<td>2.8 (1.6–3.0)</td>
<td>$&lt;0.01$</td>
</tr>
<tr>
<td>PAP/LVP</td>
<td>0.3 (0.3–0.3)</td>
<td>0.43 (0.3–0.66)</td>
<td>$&lt;0.01$</td>
</tr>
<tr>
<td>Epithelial lining fluid</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AM %</td>
<td>91.6 (85–96)</td>
<td>91.8 (81–97)</td>
<td>NS</td>
</tr>
<tr>
<td>PMN %</td>
<td>1.8 (0.7–2.9)</td>
<td>1.7 (0.5–2.7)</td>
<td>NS</td>
</tr>
<tr>
<td>LYM %</td>
<td>4.0 (2.5–8.4)</td>
<td>2.6 (1.0–15.7)</td>
<td>NS</td>
</tr>
<tr>
<td>Total protein</td>
<td>4.4 (3.0–5.7)</td>
<td>2.3 (1.6–3.2)</td>
<td>$&lt;0.02$</td>
</tr>
<tr>
<td>mgl·mL$^{-1}$</td>
<td>332 (232–602)</td>
<td>345 (n=15)</td>
<td>ND</td>
</tr>
</tbody>
</table>

Values are presented as median, and interquartile range in parenthesis. ND: not determined. For further definitions see legend to table 3.

Table 6. – Comparison of normal controls with CHD children with no lower airway viral infection

<table>
<thead>
<tr>
<th>Normal controls</th>
<th>Noninfected CHD group†</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age months</td>
<td>19.3 (7.3–49.3)</td>
<td>12.0 (4.7–17)</td>
</tr>
<tr>
<td>Weight kg</td>
<td>13.5 (7.7–17.2)</td>
<td>8.6 (5.9–10.4)</td>
</tr>
<tr>
<td>Bronchoalveolar lavage fluid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Return %</td>
<td>55 (46–60)</td>
<td>47 (36–54)</td>
</tr>
<tr>
<td>Total cells x10$^6$·mL$^{-1}$</td>
<td>175 (80–190)</td>
<td>175 (115–240)</td>
</tr>
<tr>
<td>AM %</td>
<td>93 (90–97)</td>
<td>91 (85–96)</td>
</tr>
<tr>
<td>PMN %</td>
<td>0.6 (0.3–1.5)</td>
<td>1.6 (0.4–2.9)</td>
</tr>
<tr>
<td>LYM %</td>
<td>4.6 (2.0–7.4)</td>
<td>4.0 (2.3–8.6)</td>
</tr>
<tr>
<td>ET-1 above assay detection limit‡</td>
<td>n=6 (23%)</td>
<td>n=30 (83%)</td>
</tr>
</tbody>
</table>

Values are presented as median, and interquartile range in parenthesis. †: in whom endothelin-1 was analysed; ‡: detection limit 2.5 pg·mL$^{-1}$. For definitions see legend to table 3.

Discussion

In this study, we have demonstrated that LRT viral infection and alterations in pulmonary haemodynamics significantly influence the alveolar milieu of children with CHD. Although NB-BAL and fibroptic BAL of healthy children result in similar BALF leucocyte differentials [19], the technical aspects of NB-BAL have not yet been fully described. However, in the present study, the high proportion of alveolar macrophages and the relatively low proportion of tracheal ciliated epithelial cells in NB-BALF, suggests that cells and solutes were sampled from the alveoli [20]. Furthermore, dwell-time was always less than 30 s and any artifactual changes in the urea-estimated ELF volume were minimized [21].

In the CHD group, ELF concentrations of ET-1 were an order of magnitude above those of the plasma, suggesting different rates of ET-1 production and/or removal in the pulmonary vascular and alveolar compartments.
The source of alveolar ET-1 was not determined in the present study, but alveolar macrophages, fibroblasts and epithelial cells have the capacity to synthesize and release ET-1 locally into the alveolar milieu [7]. ET-1 was undetectable in the BALF in the majority of normal controls, a finding similar to that reported in normal adult BALF [25]. We therefore found indirect evidence for increased pulmonary ET-1 production in CHD, but the presence of multiple stimuli for ET-1 production in CHD, such as cyanosis [26] and abnormal shear forces on the pulmonary endothelium [27], could account for our inability to identify any one stimulatory factor. The role of ET-1 in the pathogenesis of haemodynamic-induced respiratory symptoms is, therefore, unclear.

The observed fall in ELF total protein with increased \( Q'pQ' \) and/or PAP/LVP in CHD children without LRT infection could result from dilution of protein by an increased volume of alveolar fluid, or diminished protein production within the alveolar space. A fall in plasma protein concentrations with increased \( Q'pQ' \)’s, another possible explanation for a fall in the ELF protein, was not seen in our cohort. Although BAL cannot be used to estimate the absolute alveolar volume, a physiological explanation for the fall in ELF protein concentration is the formation of hydrostatic (low protein) oedema and the dilution of endogenous alveolar proteins. The trend for decreased ELF total cell concentration with increased \( Q'pQ' \)’s supports an increase in the volume of alveolar fluid. Indeed, a similar fall both in the ELF total protein concentration and ELF concentration of alveolar cells has been reported during the formation of hydrostatic alveolar oedema in rats [28]. In addition, the association of noninfective LRT symptoms with high \( Q'pQ' \)’s, and noninfective LRT symptoms with low concentrations of ELF total protein are compatible with a clinically significant increase in alveolar fluid. In animal studies, increased pulmonary capillary transmural pressure (\( P_{tm} \)) from left atrial occlusion, results in the formation of protein-rich "permeability" oedema in the alveoli [29]. However, these experiments utilize acute and massive elevations in \( P_{tm} \) and are not comparable with the chronic, flow-related changes in \( P_{tm} \) in human CHD.

In the CHD group, viral LRT infection profoundly altered cellularity and protein in the ELF. The viruses detected in the BALF were similar to those causing community-acquired respiratory disease in normal children [30, 31]. It is possible that the more sensitive detection technique of polymerase chain reaction (PCR) would have identified additional children as potentially infected, but the specificity of PCR when applied to BALF is unknown. The presence of high concentrations of Moraxella catarrhalis and visible intracellular organisms in over half of the virus-infected CHD group was unexpected. Although LRT infection with M. catarrhalis and Haemophilus influenzae have been described in association with viral LRT infections [32], the LRT in CHD has not previously been studied. We cannot distinguish the effect of viral infection from viral/bacterial co-infection on the ELF parameters, because of the small numbers of infected children. However, the increase in ELF protein is consistent with the increased permeability of the epithelial-capillary barrier to protein (i.e. "permeability" oedema) reported in the upper respiratory tract of adults with viral colds [33].

Variable increases in alveolar lymphocytes and neutrophils occur during experimental viral infections [9, 10]. Similarly, we found that LRT viral infection was associated with either an ELF neutrophilia or an ELF lymphocytosis. Since, by definition, the alveolar macrophage differential falls with both increased neutrophil and lymphocyte differential counts, the macrophage differential was the most sensitive marker of infection-induced inflammation. Although our cut-off point was defined retrospectively, an alveolar macrophage differential of \( \geq 80\% \) would exclude all the infected CHD children (fig. 1).

Since respiratory symptoms due to increased pulmonary blood flow did not affect the alveolar macrophage differential, BAL performed during preoperative catheterization may have a future role. If the macrophage differential is normal at catheterization, the surgeon can be rapidly reassured that respiratory infection is unlikely, even if the child exhibits tachypnoea and wheezing. If the macrophage differential is depressed, surgery could be delayed until viral cultures are available.

In conclusion, at least two factors in congenital heart disease that influence the alveolar milieu, pulmonary haemodynamics and infection. We have demonstrated a decrease in protein concentration in the epithelial lining fluid associated with increased pulmonary blood flow, and speculate that this reflects the formation of protein-depleted hydrostatic oedema in the alveoli. We could not define which factor in congenital heart disease predisposes to the accumulation of endothelin-1 in the epithelial lining fluid and the relationship between alveolar endothelin-1 and lower respiratory tract symptoms remains unclear. Nonbronchoscopic bronchoalveolar lavage of children undergoing cardiac catheterization not only provides insights into cardiopulmonary interactions, but also appears to be a promising method for rapidly assessing the infection status of the lower airway.

Acknowledgements: The authors are grateful to the Department of Microbiology and Infectious Diseases, and The Department of Virology, Royal Children's Hospital, Melbourne for their technical support.

References

6. Vincent JA, Ross RD, Kassab J, Hsu JM, Pinsky WW. Relation of elevated plasma endothelin in congenital heart


